Coronavirus: Mutations threaten to make him resistant to vaccines and drugs



Scientists are stepping up their surveillance for new coronavirus mutations, as concerns are raised that the virus could develop even partial tolerance to antibody therapies and coronavirus vaccines. There is no evidence that mutations that have been identified so far will could have helped the killer virus avoid the effects of the vaccines or treatments currently being developed, but genetic analysis of the strains currently circulating shows that it is not unlikely that partially resistant strains of the virus will emerge, which will then spread to humans. A study by the British Government’s Committee of Experts (Sage) states that the virus protein that forms the characteristic “crown” and allows it to invade human cells has undergone a series of mutations. Fears about vaccines Because many of the candidates Vaccines use this protein to induce immunity to the virus, mutations that cause significant changes in the ‘crown’ can affect the effectiveness of this immunity. “Anything that affects the crown protein can potentially change the way it is caused either by natural “Jeffrey Barrett, a geneticist and member of the Sanger Institute consortium near Cambridge, told the Guardian that the coronavirus is relatively genetically stable, but creating a series of genealogies that geneticists can use to monitor the course of the virus around the world, but also from one outbreak to another. Some genealogies are expected to show random mutations in the corona protein, in a process called “antigenic change.” Many of them may weaken the virus’s ability to spread, while others may be neutral or help it spread faster. Which treatments are most at risk? The potential risk is when the virus accumulates mutations in the protein crown, resulting in changes so much that antibody therapies and vaccines lose their effect. This risk is higher for antibody therapies, such as that given to Donald Trump, in which patients receive a mixture of two different types of antibodies. Vaccines tend to produce a greater variety of antibodies, so even if some of them prove ineffective, others should be able to fight the virus. Scientists describe how in the spring more than 500 people in Scotland stuck to a coronavirus with a protein mutation called N439K. The mutated version disappeared during the lockdown, but later reappeared in Romania, Norway, Switzerland, Ireland, Belgium and Germany, and is now available in the UK. The mutation, and more than a dozen more, show that the coron protein can be altered without making the virus non-communicable. Scientists have already shown that the N439K mutant coronavirus is resistant to at least one type of antibody produced by some patients. . The goal of virus surveillance is to identify future mutations that could, over time, make it resistant to a wider range of antibodies. Anxiety about the future The geneticist consortium is setting up a monitoring team for new and existing mutations to ensure that any signs of potential resistance detected immediately. “It is particularly important to establish monitoring of antigenic change before a vaccination program is developed in Britain, as many of the vaccines being developed target the protein crown,” said Paul Binias, a Rockefeller University virologist in New York. The Guardian says that monitoring genetic coronavirus mutations is important in order to be able to predict future problems and not because there is an immediate threat of mutations currently circulating. Need for monitoring The sporadic appearance of mutations resistant to antibodies such as N439K, is one of the reasons most treatments rely on two antibody cocktails. But Binias says that depending on how widespread the use of these therapies is, “it will be important to monitor the resistance of the virus to them, in the same way that we monitor the resistance of bacteria to antibiotics or HIV to antiviral drugs.” A single mutation is unlikely to make the coronavirus vaccine insufficient, he added, but as the virus continues to evolve over the years, pharmaceutical companies may have to redesign their vaccines to take genetic changes into account. Follow it on Google News and be the first to know all the news See all the latest news from Greece and the world, at



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *